AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01872481 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: A coil with similar appearance to the active coil in shape and weight, producing a similar sound artifact but without emission of a magnetic pulse is used for the control group.
Study NCT02997332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered every 3 weeks for 3 injections at week 1, 4, 7. Dose levels: the durvalumab first dose level is 1120 mg Q3W, and the dose level -1 is 750 mg Q3W.
Study NCT02997332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m² on D2, IV in 1 hour
Study NCT02997332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75mg/m² on D2, IV in 3 hours
Study NCT02997332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Fluorouracil
Description: 5 Fluorouracil 750mg/m²/day on D2, D3, D4, D5, D6 IV in 24 hours
Study NCT02023359 — intervention group
Intervention type: DRUG
Intervention: Everolimus and exemestane
Study NCT01021709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (Eldith DC-Stimulator (CE certified))
Description: tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm = 35 cm2 \& 10 x 10 cm = 100 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
Study NCT02375451 — intervention group
Intervention type: OTHER
Intervention: Radioiodine
Description: We will determine if prior radioiodine treatment in childhood impacts salivary function or symptoms. Radioiodine treatment will have been determined by the patient's medical condition and care (NOT assigned by this research study).
Study NCT03553381 — intervention group
Intervention type: OTHER
Intervention: hypocaloric balanced diet
Study NCT04003766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: biopsy
Description: Liver biopsy (LB) is essential for the diagnosis and evaluation of a variety of hepatic conditions, such as grading/staging of chronic liver disease secondary to alcohol, non-alcoholic steatohepatitis, viral hepatitis, hemochromatosis, Wilson's disease, cholestatic liver disease, as well as in elucidating the etiology of elevation in liver tests.
Study NCT00517036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA omega-3 fatty acid
Description: 1 gram per day of an EPA-enriched mixture for 8 weeks
Study NCT00517036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA omega-3 fatty acid
Description: 1 gram per day of pure DHA for 8 weeks
Study NCT00517036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: 1 gram per day of an inactive substance for 8 weeks
Study NCT02263040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose
Description: Influenza vaccine
Study NCT02263040 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone (standard dose)
Description: Influenza vaccine
Study NCT00416598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation
Description: Undergo autologous bone marrow transplantation
Study NCT00416598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSC transplantation
Study NCT00416598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT00416598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT00416598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT00416598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT00416598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00416598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT00416598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00416598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01266746 — intervention group
Intervention type: PROCEDURE
Intervention: Vitreous surgery
Description: Vitreous surgery is performed to treat the original disease not for the study.
Study NCT02781805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: 10 mg (1 tablet) once daily for 1-3 weeks before breast surgery; drug will be discontinued the day before surgery.
Study NCT01613690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 is administered via a BREEZHALER device
Study NCT00848796 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Heparin Leo and Hepalean
Description: Dosage based on Heparin does response curve obtained from the Medtronic HMS plus
Study NCT01509261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: 20mg/Tap, QD
Study NCT01509261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: 30mg/Tap, QD
Study NCT03513744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: human milk oligosaccharides
Description: mixture of five different human milk oligosaccharides
Study NCT02646709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Low dose rocuronium (0.3 mg/kg) will be injected after induction of anesthesia with ketamine.
Study NCT02646709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine 1
Description: ketamine 1 mg/kg will be injected for induction of anesthesia
Study NCT02646709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine 1.5
Description: ketamine 1.5 mg/kg will be injected for induction of anesthesia
Study NCT02646709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine 2
Description: ketamine 2 mg/kg will be injected for induction of anesthesia
Study NCT01546506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gutron® treatment
Description: Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
Study NCT00676104 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CoolSystems Discrete Cerebral Hypothermia System
Description: The CoolSystems Discrete Cerebral Hypothermia System (DCHS) will be removed from the patients head after 48 hours.
Study NCT00676104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSystems Discrete Cerebral Hypothermia System
Description: The CoolSystems Discrete Cerebral Hypothermia System (DCHS) will be removed from the patients head after 48 hours.
Study NCT02422680 — intervention group
Intervention type: PROCEDURE
Intervention: No intervention, purely observational.
Description: No intervention is made other than following existing guidelines for colonoscopy. Further treatment and/or renewed colonoscopy in case of positive findings follows existing guidelines. The group is used only used to collect quality assurance data.
Study NCT00475644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Description: Administered orally
Study NCT01949181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung surgery
Study NCT03439358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Bolus infusion: 100mL normal saline with 4g MgSO4 over 30 minutes Maintenance infusion: 25mL normal saline per hour with 1g MgSO4
Study NCT03439358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Bolus infusion: 100mL normal saline over 30 minutes Maintenance infusion: 25mL normal saline per hour
Study NCT04009031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bootle Blast
Description: During the baseline assessment, an occupational therapist will calibrate the video game to the child's therapy needs and functional abilities. Within a week of the first assessment, the research team will set up the video game in the participant's home where it will remain for 12 weeks. Training on how to play the game and a user manual will be provided. The researcher will work with each family to establish a play objective (minutes/day and days/week) that considers the family's schedule. Five-minute telephone check-in calls will be done weekly.
Study NCT03740243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Buprenorphine/naloxone tablet or film
Study NCT03740243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine tablet
Study NCT02622399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project NOW
Description: This intervention aims to reduce social isolation and promote engagement in health promoting enrichment and activities, by embedding a community health worker-assisted forum in a community-driven mobile communications through a private, secure, and confidential platform supported by txtwire. The principal innovation is harnessing both the behavioral change utility of a mobile health application and the social support potential of an online social network the investigators can deliver more timely and dynamic reinforcement to caregivers and social support more in rhythm with the pace of community events and stressors.
Study NCT02356705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam 0.2 mg/kg given intranasally
Study NCT02356705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xylocaine
Description: intransal xylocaine given in conjunction with intranasal midazolam
Study NCT02356705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: intranasal saline given as placebo
Study NCT01131104 — intervention group
Intervention type: DRUG
Intervention: PDE5 Inhibitors
Description: Observational study of participants who have been prescribed phosphodiesterase type 5 (PDE5) inhibitors by their physician during routine clinical practice.
Study NCT01762332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Base level of remifentanil effect side concentration: 2ng/ml
Description: constant remifentanil level of 2ng/ml administered using Target Control Infusion pumps.
Study NCT01762332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Base level of remifentanil effect side concentration: 4ng/ml
Description: constant remifentanil level of 4ng/ml administered using Target Control Infusion pumps.
Study NCT01762332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chronic beta-blocker treatment
Description: Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group.
Study NCT01762332 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: chronic beta-blocker treatment
Description: Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group.
Study NCT03024892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG GB
Description: ICG was given by intra-gallbladder injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
Study NCT03024892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG IV
Description: ICG was given by systemic injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
Study NCT03024892 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: LC conventional
Description: simple laparoscopic cholecystectomy was performed under white light image.
Study NCT03024892 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: LC conventional and IOC
Description: simple laparoscopic cholecystectomy was performed under white light image and intraoperaitve cholangiography guidance.
Study NCT00304382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)
Study NCT00304382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax
Description: 0.5 ml IM one time
Study NCT03038035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLC901
Description: 24 weeks intervention with orally MLC901. 2 capsules 3 times a day
Study NCT03038035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 weeks intervention with orally placebo. 2 capsules 3 times a day
Study NCT00524186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00524186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00524186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00524186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Taken Orally
Study NCT00524186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative Study
Study NCT00524186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative Study
Study NCT00507858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Starting dose of 500 mg/m\^2 IV Once Over 10 Minutes Every 3 Weeks
Study NCT00507858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Arm 2 = 20 mg IV On Day 1; Arm 3 = 4 mg oral (PO) Twice Daily for 3 Days
Study NCT02209818 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser Irradiation One dose
Study NCT02209818 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser Irradiation Two doses
Study NCT04243226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telehealth-based aerobic walking exercise
Description: The aim of this study is to develop exercise prescription of TBI patients and then to evaluate the effectiveness of programmed aerobic exercise to improve psysical-psycho-social health such as cognitive status, 6 minutes walk test, depression relief, motivation, symptom, resilience and quality of life.
Study NCT02918097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Study NCT02918097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Study NCT02918097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Study NCT02918097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Study NCT04854941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotics (10\^9 CFU of each strain: Lactobacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911 and Bifidobacterium longum PDV 2301) 3 times per day in addition to standard treatment regimen for 2 weeks
Study NCT03153345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bedside respiratory muscle training
Description: The program consisted of three sessions: (1) 10 minutes of breath stacking exercise, followed by (2) 10 minutes of inspiratory muscle training using a flow-oriented incentive spirometer and (3) 10 minutes of expiratory muscle training using Acapella vibratory PEP device.
Study NCT03153345 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional stroke rehabilitation program
Description: The program consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training.
Study NCT03153345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional stroke rehabilitation program
Description: The program consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training.
Study NCT04645329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shoulder immovilization sling
Description: immobilization of the arm after surgery
Study NCT04645329 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder immovilization sling
Description: immobilization of the arm after surgery
Study NCT00743847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.
Study NCT01003119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Addiction CHESS
Description: Smartphone with ACHESS application loaded onto the phone.
Study NCT00730015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Oral, once daily
Study NCT00730015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral, once daily
Study NCT00580489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: either fentanyl or morphine
Description: either morphine 4mg IV or fentanyl 50mcg IV
Study NCT00983749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full-pressure ECP
Description: A one-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner, starting at 200mmHg and increasing up to 300mmHg based on assessments made.
Study NCT00743847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.
Study NCT00743847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.
Study NCT01317004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: 0.5 mg/day oral capsule
Study NCT01317004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard MS DMT
Description: Interferon beta 1a or interferon beta 1b or Glatiramer Acetate
Study NCT03876496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensableCare System
Description: The Sensable®Care Mattress has sensors embedded in it. Sensable®Care System is able to identify if the subject is stirring in bed, sitting up from the bed, attempting to leave the bed, or being out of the bed. If the subject is found to be in any of these four scenarios, four different types of alerts/notifications will warn clinicians: Stirring Notification, Sitting Up Notification, Bed Leaving Alert, Out of Bed Alert, will be generated by Sensable®Care System respectively.~Once these four alerts/notifications are generated, designated attending nurses or caregivers equipped with a mobile app will receive audible, vibratory, and/or visual alerts from the Dashboard with subject's room number and type of alert displayed mobile app. Thus, interventions/assistance can be carried out presumably early. Harm to patient safety may be prevented.
Study NCT00499343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m\^2 given intravenously over 2 hours every 12 hours x 6 doses.
Study NCT00499343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Starting dose on day +6 at 6 mcg/kg injection every 12 hours until completion of apheresis.
Study NCT00499343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 mcg/m\^2 injection given every evening till the completion of apheresis.
Study NCT00499343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isophosphamide
Description: 10 g/m\^2 given intravenously continuous infusion over 72 hours.
Study NCT00983749 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-pressure ECP
Description: A one-hour treatment of ECP at an inactive pressure, which will be applied at 75mmHg and kept there for the hour while assessments are made.
Study NCT02130245 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early cholecystectomy
Description: Early laparoscopic cholecystectomy for acute cholecystitis after admission
Study NCT02130245 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cholecystectomy
Description: Laparoscopic cholecystectomy well be done after a period on conservation
Study NCT02957955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks. Participants will complete six-minute walk test, cardiopulmonary exercise test, and six questionnaires: Short Form 36 Health Survey Questionnaire (SF-36), Minnesota Living with Heart Failure Questionnaire (MLHFQ), Beck Depression Inventory II (BDI-II), Beck Anxiety Inventory (BAI), Montreal Cognitive Assessment (MOCA), and Impact of Events Scale-Revised (IES-R) at baseline (week 1) and follow-up (after 12 weeks of intervention).